These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12225331)

  • 21. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.
    Polyak SJ; McArdle S; Liu SL; Sullivan DG; Chung M; Hofgärtner WT; Carithers RL; McMahon BJ; Mullins JI; Corey L; Gretch DR
    J Virol; 1998 May; 72(5):4288-96. PubMed ID: 9557719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein.
    Fukuma T; Enomoto N; Marumo F; Sato C
    Hepatology; 1998 Oct; 28(4):1147-53. PubMed ID: 9755255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy.
    Halfon P; Halimi G; Bourlière M; Ouzan D; Durant J; Khiri H; Mercier L; Gerolami V; Cartouzou G
    Liver; 2000 Oct; 20(5):381-6. PubMed ID: 11092256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.
    Gale M; Blakely CM; Kwieciszewski B; Tan SL; Dossett M; Tang NM; Korth MJ; Polyak SJ; Gretch DR; Katze MG
    Mol Cell Biol; 1998 Sep; 18(9):5208-18. PubMed ID: 9710605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Construction and sequence analysis of recombinant HCV-1b replicon by replacing NS5A region].
    Li J; Zhou B; Zhou Y; Zeng Y; Li W; Wang J; Zhang J; Zhang H; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jan; 32(1):46-9. PubMed ID: 22366003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
    Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
    J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
    Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
    Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection.
    Aslan N; Bozdayi AM; Cetinkaya H; Sarioğlu M; Türkay C; Bozkaya H; Karayalçin S; Yurtaydin C; Uzunalimoğlu O
    Turk J Gastroenterol; 2004 Mar; 15(1):21-6. PubMed ID: 15264117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
    Malta Fde M; Medeiros-Filho JE; Azevedo RS; Gonçalves L; Silva LC; Carrilho FJ; Pinho JR
    Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):92-8. PubMed ID: 20209336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.
    Odeberg J; Yun Z; Sönnerborg A; Weiland O; Lundeberg J
    J Med Virol; 1998 Sep; 56(1):33-8. PubMed ID: 9700630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus: the role of molecular mimicry in response to interferon treatment.
    Uzicanin S; Hu YW; Alsousi H; Pelchat M; Rocheleau L; Nair RC; Brown EG
    J Med Virol; 2012 Oct; 84(10):1571-85. PubMed ID: 22930505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
    Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
    J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.